Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
IVVD
IVVD
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
IVVD News
BETA Technologies Reports Disappointing Q4 Results
1d ago
Benzinga
Invivyd Q4 2025 Earnings Call Highlights
5d ago
seekingalpha
Invivyd Reports Q4 2025 Financial Results and Clinical Trial Updates
5d ago
Newsfilter
Invivyd Set to Announce FY Earnings with Significant Growth Expectations
6d ago
seekingalpha
Invivyd Aligns with FDA on LIBERTY Phase 3 Trial for VYD2311
Feb 03 2026
seekingalpha
Invivyd Launches LIBERTY Clinical Trial for VYD2311
Feb 03 2026
Newsfilter
Invivyd Initiates Phase 2 Trial for VYD2311 Targeting Long COVID Patients
Jan 20 2026
Newsfilter
Invivyd Reports Q4 2025 Revenue of $17.2M, Up 25% Year-over-Year
Jan 08 2026
Globenewswire
Invivyd Receives FDA Fast Track Designation for VYD2311 Vaccine
Dec 23 2025
Globenewswire
Invivyd Initiates Phase 3 DECLARATION Trial for VYD2311 with 1770 Participants
Dec 23 2025
Globenewswire
BTIG Initiates Buy Rating on Invivyd Inc with $10 Price Target
Dec 22 2025
Benzinga
Staar Surgical and Gold Royalty Experience Activist Involvement
Nov 26 2025
Barron's
Coinbase Analyst Changes Stance; Check Out Tuesday's Top 5 Downgrades
Nov 25 2025
Benzinga
Invivyd Unveils VBY329 Monoclonal Antibody for RSV Prevention, Targeting $4 Billion Market
Nov 24 2025
Newsfilter
Major Stocks Including Helmerich and Payne, Invivyd, and Home Depot Decline in Tuesday's Pre-Market Trading
Nov 18 2025
Benzinga
Gorilla Technology Shares Rise Approximately 14%; Check Out 20 Stocks Making Moves in Premarket Trading
Nov 18 2025
Benzinga
Show More News
